Alnylam's (ALNY) Strong ALN-PCSsc Data at AHA Conference, FBR Capital Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Medicines Co. (MDCO), Alnylam' (ALNY) ALN-PCSsc Data Affirm Potential bi-Annual Dose Regimen - Chardan Capital
November 11, 2015 12:35 PM ESTChardan Capital affirms Medicines Company (Nasdaq: MDCO) with a Buy rating and $50 price target after the company and Alnylam (Nasdaq: ALNY)... More
Alnylam Pharma (ALNY), Medicines Co. (MDCO) Announce Positive Data from Ongoing ALN-PCSsc Phase 1
November 11, 2015 10:47 AM ESTAlnylam Pharma (NASDAQ: ALNY) and The Medicines Company (Nasdaq: MDCO) reported positive results from their ongoing Phase 1 clinical trial with ALN-PCSsc in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2015.
ALN-PCSsc is an investigational RNAi therapeutic... More
Medicines (MDCO)/Alnylam (ALNY) to Present Phase 1 Data on siRNA-based PCSK9 Today
November 11, 2015 8:23 AM ESTEvercore ISI analyst Umer Raffat notes Medicines Co. (NASDAQ: MDCO)/Alnylam Pharma (NASDAQ: ALNY) will present updated Ph 1 data on their siRNA-based PCSK9 at AHA late breaker today/
Below are key things Raffat is... More
